Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy.
| Autor: | Hallqvist, A.1,2 andreas.hallqvist@oncology.gu.se, Enlund, F.3, Andersson, C.3, Sjögren, H.4, Hussein, A.3, Holmberg, E.1, Nyman, J.1 |
|---|---|
| Zdroj: | Lung Cancer International. 2012, p1-6. 6p. 5 Charts, 1 Graph. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|